Therapeutic targeting of p53 by small molecules

Seminars in Cancer Biology

Volumn 20, Issue 1, 2010, Pages 46-56

  Selivanova, Galina ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Anti cancer therapy; Apoptosis; Growth arrest; P53; Small molecules

Indexed keywords

4 (3 DIMETHYLAMINOPROPYLAMINO) 2 (4 METHOXYSTYRYL)QUINAZOLINE; ANTINEOPLASTIC AGENT; APR 246; COMPOUND P53R3; NUTLIN 3; PRIMA 1 COMPOUND; PROTEIN MDM2; PROTEIN MDMX; PROTEIN P53; RITA COMPOUND; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BREAST CARCINOMA; CANCER INHIBITION; CANCER REGRESSION; CARCINOGENESIS; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; CONFORMATIONAL TRANSITION; DISEASE MODEL; DRUG DESIGN; DRUG EFFICACY; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG TARGETING; GENETIC MANIPULATION; HEMATOLOGIC MALIGNANCY; HUMAN; LUNG CARCINOMA; NONHUMAN; OSTEOSARCOMA; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REVIEW; SKIN CANCER; SOLID TUMOR; TUMOR XENOGRAFT; WILD TYPE;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; NEOPLASMS; SMALL MOLECULE LIBRARIES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 77952543382     PISSN: 1044579X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semcancer.2010.02.006     Document Type: Review

References (104)

1. Cancer Geome Atlas network Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008, 455(7216):1061-1068.
2. Sjöblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D., et al. The consensus coding sequences of human breast and colorectal cancers. Science 2006, 314(5797):268-274.
3. Vogelstein B., Lane D., Levine A.J. Surfing the p53 network. Nature 2000, 408(6810):307-310.
4. Selivanova G. p53: fighting cancer. Curr Cancer Drug Targets 2004, 4(5):385-402.
5. Olivier M., Eeles R., Hollstein M., Khan M.A., Harris C.C., Hainaut P. The IARC TP53 database: new online mutation analysis and recommendations to users. Hum Mutat 2002, 19(6):607-614.
6. Vousden K.H., Lu X. Live or let die: the cell's response to p53. Nat Rev Cancer 2002, 2(8):594-604.
7. Dey A., Verma C.S., Lane D.P. Updates on p53: modulation of p53 degradation as a therapeutic approach. Br J Cancer 2008, 98(1):4-8.
8. Vousden K.H. Lane DP. p53 in health and disease. Nat Rev Mol Cell Biol 2007, 8(4):275-283.
9. Vassilev L.T. MDM2 inhibitors for cancer therapy. Trends Mol Med 2007, 13(1):23-31.
10. Selivanova G., Wiman K.G. Reactivation of mutant p53: molecular mechanisms and therapeutic potential. Oncogene 2007, 26(15):2243-2254.
11. Bassett E.A., Wang W., Rastinejad F., El-Deiry W.S. Structural and functional basis for therapeutic modulation of p53 signaling. Clin Cancer Res 2008, 14(20):6376-6386.
12. Riley T., Sontag E., Chen P., Levine A. Transcriptional control of human p53-regulated genes. Nat Rev Mol Cell Biol 2008, 9(5):402-412.
13. Vaseva A.V., Moll U.M. The mitochondrial p53 pathway. Biochim Biophys Acta 2009, 1787(5):414-420.
14. Vousden K.H., Prives C. Blinded by the light: the growing complexity of p53. Cell 2009, 137(3):413-431.
15. Budanov A.V., Sablina A.A., Feinstein E., Koonin E.V., Chumakov P.M. Regeneration of peroxiredoxins by p53-regulated sestrins, homologs of bacterial AhpD. Science 2004, 304(5670):596-600.
16. Sablina A.A., Budanov A.V., Ilyinskaya G.V., Agapova L.S., Kravchenko J.E., Chumakov P.M. The antioxidant function of the p53 tumor suppressor. Nat Med 2005, 11(12):1306-1313.
17. Gatz S.A., Wiesmuller L. p53 in recombination and repair. Cell Death Differ 2006, 13(6):1003-1016.
18. Liu G., Parant J.M., Lang G., Chau P., Chavez-Reyes A., El-Naggar A.K., et al. Chromosome stability, in the absence of apoptosis, is critical for suppression of tumorigenesis in Trp53 mutant mice. Nat Genet 2004, 36(1):63-68.
19. Matheu A., Maraver A., Klatt P., Flores I., Garcia-Cao I., Borras C., et al. Delayed ageing through damage protection by the Arf/p53 pathway. Nature 2007, 448(7151):375-379.
20. Matheu A., Maraver A., Collado M., Garcia-Gao I., Canamero M., Borras C., et al. Anti-aging activity of the Ink4/Arf locus. Aging Cell 2009, 8(2):152-161.
21. Gudkov A.V., Komarova E.A. Dangerous habits of a security guard: the two faces of p53 as a drug target. Hum Mol Genet 2007, 16(Spec No 1):R67-72.
22. Gatza C., Moore L., Dumble M., Donehower L.A. Tumor suppressor dosage regulates stem cell dynamics during aging. Cell Cycle 2007, 6(1):52-55.
23. Tyner S.D., Venkatachalam S., Choi J., Jones S., Ghebranious N., Igelmann H., et al. p53 mutant mice that display early ageing-associated phenotypes. Nature 2002, 415(6867):45-53.
24. Moreno C.S., Matyunina L., Dickerson E.B., Schubert N., Bowen N.J., Logani S., et al. Evidence that p53-mediated cell-cycle-arrest inhibits chemotherapeutic treatment of ovarian carcinomas. PLoS One 2007, 2(5):e441.
25. Bertheau P., Espie M., Turpin E., Lehmann J., Plassa L.F., Varna M., et al. TP53 status and response to chemotherapy in breast cancer. Pathobiology 2008, 75(2):132-139.
26. Amaravadi R.K., Yu D., Lum J.J., Bui T., Christophorou M.A., Evan G.I., et al. Autophagy inhibition enhances therapy-induced apoptosis in a Myc-induced model of lymphoma. J Clin Invest 2007, 117(2):326-336.
27. Kruse J.P., Gu W. Modes of p53 regulation. Cell 2009, 137(4):609-622.
28. D'Orazi G., Cecchinelli B., Bruno T., Manni I., Higashimoto Y., Saito S., et al. Homeodomain-interacting protein kinase-2 phosphorylates p53 at Ser 46 and mediates apoptosis. Nat Cell Biol 2002, 4(1):11-19.
29. Lu X. p53: a heavily dictated dictator of life and death. Curr Opin Genet Dev 2005, 15(1):27-33.
30. Moumen A., Masterson P., O'Connor M.J., Jackson S.P. hnRNP K: an HDM2 target and transcriptional coactivator of p53 in response to DNA damage. Cell 2005, 123(6):1065-1078.
31. Enge M., Bao W., Hedstrom E., Jackson S.P., Moumen A., Selivanova G. MDM2-dependent downregulation of p21 and hnRNP K provides a switch between apoptosis and growth arrest induced by pharmacologically activated p53. Cancer Cell 2009, 15(3):171-183.
32. MacLachlan T.K., Takimoto R., El-Deiry W.S. BRCA1 directs a selective p53-dependent transcriptional response towards growth arrest and DNA repair targets. Mol Cell Biol 2002, 22(12):4280-4292.
33. Seo Y.R., Kelley M.R., Smith M.L. Selenomethionine regulation of p53 by a ref1-dependent redox mechanism. Proc Natl Acad Sci USA 2002, 99(22):14548-14553.
34. Samuels-Lev Y., O'Connor D.J., Bergamaschi D., Trigiante G., Hsieh J.K., Zhong S., et al. ASPP proteins specifically stimulate the apoptotic function of p53. Mol Cell 2001, 8(4):781-794.
35. Harvey M., McArthur M.J., Montgomery C.A., Bradley A., Donehower L.A. Genetic background alters the spectrum of tumors that develop in p53-deficient mice. FASEB J 1993, 7(10):938-943.
36. Maier B., Gluba W., Bernier B., Turner T., Mohammad K., Guise T., et al. Modulation of mammalian life span by the short isoform of p53. Genes Dev 2004, 18(3):306-319.
37. Montes de Oca Luna R., Wagner D.S., Lozano G. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature 1995, 378(6553):203-206.
38. Parant J., Chavez-Reyes A., Little N.A., Yan W., Reinke V., Jochemsen A.G., et al. Rescue of embryonic lethality in Mdm4-null mice by loss of Trp53 suggests a nonoverlapping pathway with MDM2 to regulate p53. Nat Genet 2001, 29(1):92-95.
39. Christophorou M.A., Martin-Zanca D., Soucek L., Lawlor E.R., Brown-Swigart L., Verschuren E.W., et al. Temporal dissection of p53 function in vitro and in vivo. Nat Genet 2005, 37(7):718-726.
40. Ringshausen I., O'Shea C.C., Finch A.J., Swigart L.B., Evan G.I. Mdm2 is critically and continuously required to suppress lethal p53 activity in vivo. Cancer Cell 2006, 10(6):501-514.
41. García-Cao I., García-Cao M., Martín-Caballero J., Criado L.M., Klatt P., Flores J.M., et al. Super p53" mice exhibit enhanced DNA damage response, are tumor resistant and age normally. EMBO J 2002, 21(22):6225-6235.
42. Tomás-Loba A., Flores I., Fernández-Marcos P.J., Cayuela M.L., Maraver A., Tejera A., et al. Telomerase reverse transcriptase delays aging in cancer-resistant mice. Cell 2008, 135(4):609-622.
43. Martins C.P., Brown-Swigart L., Evan G.I. Modeling the therapeutic efficacy of p53 restoration in tumors. Cell 2006, 127(7):1323-1334.
44. Xue W., Zender L., Miething C., Dickins R.A., Hernando E., Krizhanovsky V., et al. Senescence and tumor clearance is triggered by p53 restoration in murine liver carcinomas. Nature 2007, 445(7128):656-660.
45. Ventura A., Kirsch D.G., McLaughlin M.E., Tuveson D.A., Grimm J., Lintault L., et al. Restoration of p53 function leads to tumor regression in vivo. Nature 2007, 445(7128):661-665.
46. Bartkova J., Horejsi Z., Koed K., Krämer A., Tort F., Zieger K., et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 2005, 434(7035):864-870.
47. Gorgoulis V.G., Vassiliou L.V., Karakaidos P., Zacharatos P., Kotsinas A., Liloglou T., et al. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature 2005, 434(7035):907-913.
48. Luo J., Solimini N.L., Elledge S.J. Principles of cancer therapy: oncogene and non-oncogene addiction. Cell 2009, 136(5):823-837.
49. Hamroun D., Kato S., Ishioka C., Claustres M., Beroud C., Soussi T. The UMD TP53 database and website: update and revisions. Hum Mutat 2006, 27(1):14-20.
50. Terzian T., Suh Y.A., Iwakuma T., Post S.M., Neumann M., Lang G.A., et al. The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss. Genes Dev 2008, 22(10):1337-1344.
51. Selivanova G. Mutant p53: the loaded gun. Curr Opin Invest Drugs 2001, 2(8):1136-1141.
52. Selivanova G., Iotsova V., Okan I., Fritsche M., Ström M., Groner B., et al. Restoration of the growth suppression function of mutant p53 by a synthetic peptide derived from the p53 C-terminal domain. Nat Med 1997, 3(6):632-638.
53. Abarzua P., LoSardo J.E., Gubler M.L., Spathis R., Lu Y.A., Felix A., et al. Restoration of the transcription activation function to mutant p53 in human cancer cells. Oncogene 1996, 13(11):2477-2482.
54. Kim A.L., Raffo A.J., Brandt-Rauf P.W., Pincus M.R., Monaco R., Abarzua P., et al. Conformational and molecular basis for induction of apoptosis by a p53 C-terminal peptide in human cancer cells. J Biol Chem 1999, 274(49):34924-34931.
55. Selivanova G., Ryabchenko L., Jansson E., Iotsova V., Wiman K.G. Reactivation of mutant p53 through interaction of a C-terminal peptide with the core domain. Mol Cell Biol 1999, 19(5):3395-3402.
56. Snyder E.L., Meade B.R., Saenz C.C., Dowdy S.F. Treatment of terminal peritoneal carcinomatosis by a transducible p53-activating peptide. PLoS Biol 2004, 2(2):E36.
57. Gorina S., Pavletich N.P. Structure of the p53 tumor suppressor bound to the ankyrin and SH3 domains of 53BP2. Science 1996, 274(5289):1001-1005.
58. Friedler A., Hansson L.O., Veprintsev D.B., Freund S.M., Rippin T.M., Nikolova P.V., et al. A peptide that binds and stabilizes p53 core domain: chaperone strategy for rescue of oncogenic mutants. Proc Natl Acad Sci USA 2002, 99(2):937-942.
59. Issaeva N., Friedler A., Bozko P., Wiman K.G., Fersht A.R., Selivanova G. Rescue of mutants of the tumor suppressor p53 in cancer cells by a designed peptide. Proc Natl Acad Sci USA 2003, 100(23):13303-13307.
60. Foster B.A., Coffey H.A., Morin M.J., Rastinejad F. Pharmacological rescue of mutant p53 conformation and function. Science 1999, 286(5449):2507-2510.
61. Demma M.J., Wong S., Maxwell E., Dasmahapatra B. CP-31398 restores DNA-binding activity to mutant p53 in vitro but does not affect p53 homologs p63 and p73. J Biol Chem 2004, 279(44):45887-45896.
62. Rippin T.M., Bykov V.J., Freund S.M., Selivanova G., Wiman K.G., Fersht A.R. Characterization of the p53-rescue drug CP-31398 in vitro and in living cells. Oncogene 2002, 21(14):2119-2129.
63. Luu Y., Bush J., Cheung K.J., Li G. The p53 stabilizing compound CP-31398 induces apoptosis by activating the intrinsic Bax/mitochondrial/caspase-9 pathway. Exp Cell Res 2002, 276(2):214-222.
64. Wang W., Takimoto R., Rastinejad F., El-Deiry W.S. Stabilization of p53 by CP-31398 inhibits ubiquitination without altering phosphorylation at serine 15 or 20 or MDM2 binding. Mol Cell Biol 2003, 23(6):2171-2181.
65. Stanhope-Baker P., Kessler P.M., Li W., Agarwal M.L., Williams B.R. The Wilms tumor suppressor-1 target gene podocalyxin is transcriptionally repressed by p53. J Biol Chem 2004, 279(32):33575-33585.
66. Tang X., Zhu Y., Han L., Kim A.L., Kopelovich L., Bickers D.R., et al. CP-31398 restores mutant p53 tumor suppressor function and inhibits UVB-induced skin carcinogenesis in mice. J Clin Invest 2007, 117(12):3753-3764.
67. Rao C.V., Swamy M.V., Patlolla J.M., Kopelovich L. Suppression of familial adenomatous polyposis by CP-31398, a TP53 modulator, in APCmin/+ mice. Cancer Res 2008, 68(18):7670-7675.
68. Bykov V.J., Issaeva N., Shilov A., Hultcrantz M., Pugacheva E., Chumakov P., et al. Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat Med 2002, 8(3):282-288.
69. Benakanakere I., Besch-Williford C., Ellersieck M.R., Hyder S.M. Regression of progestin-accelerated 7,12-dimethylbenz[a]anthracene-induced mammary tumors in Sprague-Dawley rats by p53 reactivation and induction of massive apoptosis: a pilot study. Endocr Relat Cancer 2009, 16(1):85-98.
70. Shen J., Vakifahmetoglu H., Stridh H., Zhivotovsky B., Wiman K.G. PRIMA-1MET induces mitochondrial apoptosis through activation of caspase-2. Oncogene 2008, 27(51):6571-6580.
71. Wang T., Lee K., Rehman A., Daoud S.S. PRIMA-1 induces apoptosis by inhibiting JNK signaling but promoting the activation of Bax. Biochem Biophys Res Commun 2007, 352(1):203-212.
72. Chipuk J.E., Maurer U., Green D.R., Schuler M. Pharmacologic activation of p53 elicits Bax-dependent apoptosis in the absence of transcription. Cancer Cell 2003, 4(5):371-381.
73. Li Y., Mao Y., Brandt-Rauf P.W., Williams A.C., Fine R.L. Selective induction of apoptosis in mutant p53 premalignant and malignant cancer cells by PRIMA-1 through the c-Jun-NH2-kinase pathway. Mol Cancer Ther 2005, 4(6):901-909.
74. Shi H., Lambert J.M., Hautefeuille A., Bykov V.J., Wiman K.G., Hainaut P., et al. In vitro and in vivo cytotoxic effects of PRIMA-1 on hepatocellular carcinoma cells expressing mutant p53ser249. Carcinogenesis 2008, 29(7):1428-1434.
75. Bossi G., Marampon F., Maor-Aloni R., Zani B., Rotter V., Oren M., et al. Conditional RNA interference in vivo to study mutant p53 oncogenic gain of function on tumor malignancy. Cell Cycle 2008, 7(12):1870-1879.
76. Li Y., Prives C. Are interactions with p63 and p73 involved in mutant p53 gain of oncogenic function?. Oncogene 2007, 26(15):2220-2225.
77. Kravchenko J.E., Ilyinskaya G.V., Komarov P.G., Agapova L.S., Kochetkov D.V., Strom E., et al. Small-molecule RETRA suppresses mutant p53-bearing cancer cells through a p73-dependent salvage pathway. Proc Natl Acad Sci USA 2008, 105(17):6302-6307.
78. Rehman A., Chahal M.S., Tang X., Bruce J.E., Pommier Y., Daoud S.S. Proteomic identification of heat shock protein 90 as a candidate target for p53 mutation reactivation by PRIMA-1 in breast cancer cells. Breast Cancer Res 2005, 7(5):R765-R774.
79. Lambert J.M., Gorzov P., Veprintsev D.B., Söderqvist M., Segerbäck D., Bergman J., et al. PRIMA-1 reactivates mutant p53 by covalent binding to the core domain. Cancer Cell 2009, 15(5):376-388.
80. Nahi H., Lehmann S., Mollgard L., Bengtzen S., Selivanova G., Wiman K.G., et al. Effects of PRIMA-1 on chronic lymphocytic leukaemia cells with and without hemizygous p53 deletion. Br J Haematol 2004, 127(3):285-291.
81. Nahi H., Merup M., Lehmann S., Bengtzen S., Möllgård L., Selivanova G., et al. PRIMA-1 induces apoptosis in acute myeloid leukaemia cells with p53 gene deletion. Br J Haematol 2006, 132(2):230-236.
82. Weinmann L., Wischhusen J., Demma M.J., Naumann U., Roth P., Dasmahapatra B., et al. A novel p53 rescue compound induces p53-dependent growth arrest and sensitises glioma cells to Apo2L/TRAIL-induced apoptosis. Cell Death Differ 2008, 15(4):718-729.
83. Joerger A.C., Ang H.C., Fersht A.R. Structural basis for understanding oncogenic p53 mutations and designing rescue drugs. Proc Natl Acad Sci USA 2006, 103(41):15056-15061.
84. Boeckler F.M., Joerger A.C., Jaggi G., Rutherford T.J., Veprintsev D.B., Fersht A.R. Targeted rescue of a destabilized mutant of p53 by an in silico screened drug. Proc Natl Acad Sci USA 2008, 105(30):10360-10365.
85. Vassilev L.T., Vu B.T., Graves B., Carvajal D., Podlaski F., Filipovic Z., et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004, 303(5659):844-848.
86. Shangary S., Ding K., Qiu S., Nikolovska-Coleska Z., Bauer J.A., Liu M., et al. Reactivation of p53 by a specific MDM2 antagonist (MI-43) leads to p21-mediated cell cycle arrest and selective cell death in colon cancer. Mol Cancer Ther 2008, 7(6):1533-1542.
87. Yang Y., Ludwig R.L., Jensen J.P., Pierre S.A., Medaglia M.V., Davydov I.V., et al. Small molecule inhibitors of HDM2 ubiquitin ligase activity stabilize and activate p53 in cells. Cancer Cell 2005, 7(6):547-559.
88. Issaeva N., Bozko P., Enge M., Protopopova M., Verhoef L.G., Masucci M., et al. Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors. Nat Med 2004, 10(12):1321-1328.
89. Okorokov A.L., Sherman M.B., Plisson C., Grinkevich V., Sigmundsson K., Selivanova G., et al. The structure of p53 tumor suppressor protein reveals the basis for its functional plasticity. EMBO J 2006, 25(21):5191-5200.
90. Nahi H., Selivanova G., Lehmann S., Möllgård L., Bengtzen S., Concha H., et al. Mutated and non-mutated TP53 as targets in the treatment of leukaemia. Br J Haematol 2008, 141(4):445-453.
91. Grinkevich V.V., Nikulenkov F., Shi Y., Enge M., Bao W., Maljukova A., et al. Ablation of key oncogenic pathways by RITA-reactivated p53 is required for efficient apoptosis. Cancer Cell 2009, 15(5):441-453.
92. Shaked H., Shiff I., Kott-Gutkowski M., Siegfried Z., Haupt Y., Simon I. Chromatin Immunoprecipitation-on-Chip Reveals Stress-Dependent p53 Occupancy in Primary Normal Cells but Not in Established Cell Lines. Cancer Research 2008, 68:9671.
93. Baptiste-Okoh N., Barsotti A.M., Prives C. Caspase 2 is both required for p53-mediated apoptosis and downregulated by p53 in a p21-dependent manner. Cell Cycle 2008, 7(9):1133-1138.
94. Suzuki A., Tsutomi Y., Akahane K., Araki T., Miura M. Resistance to Fas-mediated apoptosis: activation of caspase 3 is regulated by cell cycle regulator p21WAF1 and IAP gene family ILP. Oncogene 1998, 17(8):931-939.
95. Viale A., De Franco F., Orleth A., Cambiaghi V., Giuliani V., Bossi D., et al. Cell-cycle restriction limits DNA damage and maintains self-renewal of leukaemia stem cells. Nature 2009, 457(7225):51-56.
96. Rinaldo C., Prodosmo A., Siepi F., Moncada A., Sacchi A., Selivanova G., et al. HIPK2 regulation by MDM2 determines tumor cell response to the p53-reactivating drugs nutlin-3 and RITA. Cancer Res 2009, 69(15):6241-6248.
97. Yang J., Ahmed A., Poon E., Perusinghe N., de Haven Brandon A., Box G., et al. Small-molecule activation of p53 blocks hypoxia-inducible factor 1alpha and vascular endothelial growth factor expression in vivo and leads to tumor cell apoptosis in normoxia and hypoxia. Mol Cell Biol 2009, 29(8):2243-2253.
98. Oren M. Decision making by p53: life, death and cancer. Cell Death Differ 2003, 10(4):431-442.
99. Lowe S.W., Cepero E., Evan G. Intrinsic tumor suppression. Nature 2004, 432(7015):307-315.
100. Felsher D.W., Bishop J.M. Reversible tumorigenesis by MYC in hematopoietic lineages. Mol Cell 1999, 4(2):199-207.
101. Carroll V.A., Ashcroft M. Targeting the molecular basis for tumor hypoxia. Expert Rev Mol Med 2005, 7(6):1-16.
102. Komarov P.G., Komarova E.A., Kondratov R.V., Christov-Tselkov K., Coon J.S., Chernov M.V., et al. A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy. Science 1999, 285(5434):1733-1737.
103. Strom E., Sathe S., Komarov P.G., Chernova O.B., Pavlovska I., Shyshynova I., et al. Small-molecule inhibitor of p53 binding to mitochondria protects mice from gamma radiation. Nat Chem Biol 2006, 2(9):474-479.
104. Feng Z., Hu W., Teresky A.K., Hernando E., Cordon-Cardo C., Levine A.J. Declining p53 function in the aging process: a possible mechanism for the increased tumor incidence in older populations. Proc Natl Acad Sci USA 2007, 104(42):16633-16638.